On the other hand, the ANOVA model detected the KRAS copy number alteration as a resistance biomarker for lenalidomide (immunomodulatory drug) partial sensitivity in skin cutaneous melanoma (SKCM), whilst not detected by our Bayesian approach. This evidence concerns the gene KRAS and cutaneous melanoma.